ES2558565T3 - Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina) - Google Patents
Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina) Download PDFInfo
- Publication number
- ES2558565T3 ES2558565T3 ES02727946.2T ES02727946T ES2558565T3 ES 2558565 T3 ES2558565 T3 ES 2558565T3 ES 02727946 T ES02727946 T ES 02727946T ES 2558565 T3 ES2558565 T3 ES 2558565T3
- Authority
- ES
- Spain
- Prior art keywords
- atorvastatin
- width
- diffractometer
- phenylamino
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Una forma VII cristalina de atorvastatina sesquihidratada que tienen una difracción de rayos X de polvo que contiene los siguientes valores de 2θ medidos usando radiación CuKα: 8,6, 10,2, 12,4 (ancho), 12,8 (ancho), 17,6, 18,3 (ancho), 19,3, 22,2 (ancho), 23,4 (ancho), 23,8 (ancho) y 25,5 (ancho).
Description
Adicionalmente, la presente invención se refiere a la forma VII cristalina de atorvastatina sesquihidratada caracterizada mediante el siguiente espectro Raman que tiene picos expresados en cm-1:
Espectro Raman 3060 2927 1649 1603 1524 1476 1412 1397 1368 1159 1034 998 824 114
La forma VIII cristalina de atorvastatina e hidratos de la misma se caracterizan por el siguiente patrón de difracción de rayos X de polvo expresado en términos de 2θ e intensidades relativas con una intensidad relativa de >10 % medida con un difractómetro Shimadzu con radiación CuKα:
2θ Intensidad relativa (>10 %)a
- 7,5
- 61
- 9,2
- 29
- 10,0
- 16
- 12,1
- 10
- 12,8
- 6
- 13,8
- 4
- 15,1
- 13
- 16,7 (ancho)
- 64
- 18,6 (ancho)
- 100
- 20,3 (ancho)
- 79
- 21,2
- 24
- 21,9
- 30
- 22,4
- 19
- 25,8
- 33
- 26,5
- 20
- 27,4 (ancho)
- 38
- 30,5
- 20
a Intensidad relativa de 12,8 2θ es 6 y 13,8 2θ es 4.
10 Adicionalmente, el siguiente patrón de difracción de rayos X de polvo de la forma VIII cristalina de atorvastatina expresada en términos de valores de 2θ se midió en un difractómetro Inel (capilar):
2θ
7,5
9,3
10,1
12,2
12,8
7
- 9,9
- 36
- 10,4 (ancho)
- 24
- 12,5
- 18
- 13,9 (ancho)
- 9
- 16,2
- 10
- 17,8
- 70
- 19,4
- 100
- 20,8
- 51
- 21,7
- 13
- 22,4-22,6 (ancho)
- 18
- 24,3
- 19
- 25,5
- 24
- 26,2
- 11
- 27,1
- 8
a Intensidad relativa de 13,9 (ancho) 2θ es 9y 27,12θ es 8.
Adicionalmente, el siguiente patrón de difracción de rayos X de polvo de la forma cristalina XII de atorvastatina expresada en términos de valores de 2θ se midió en un difractómetro Inel (capilar):
2θ 5,4 7,7 8,1 8,6 8,9 10,0 10,5 12,6 14,0 (ancho) 2θ 16,2 17,9 19,4 20,9 21,8 22,5-22,8 (ancho)
24,4
25,6 26,4 27,2
Adicionalmente, la forma cristalina XII de atorvastatina e hidratos de la misma se caracterizan mediante el siguiente espectro Raman que tiene picos expresados en cm-1:
Espectro Raman 3064 2973 2926 1652 1603 1527
12
5
15
25
35
45
55
65
Figura 10 Difractograma de la Forma XIV de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 11 Difractograma de la Forma XV de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 12 Difractograma de la Forma XVI de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 13 Difractograma de la Forma XVII de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 14 Difractograma de la Forma XVIII de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 15 Difractograma de la Forma XIX de atorvastatina llevado a cabo en un difractómetro Bruker D 5000.
Figura 16 Difractograma de la Forma V de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 17 Difractograma de la Forma VI de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 18 Difractograma de la Forma VII de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 19 Difractograma de la Forma VIII de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 20 Difractograma de la Forma IX de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 21 Difractograma de la Forma X de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 22 Difractograma de la Forma XII de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 23 Difractograma de la Forma XVI de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 24 Difractograma de la Forma XVIII de atorvastatina llevado a cabo en un difractómetro Inel XRG-3000.
Figura 25 Espectro de resonancia magnética nuclear de 13C en estado sólido con bandas laterales de rotación identificadas por un asterisco de la Forma V de atorvastatina.
Figura 26 Espectro de resonancia magnética nuclear de 13C en estado sólido con bandas laterales de rotación identificadas por un asterisco de la Forma VI de atorvastatina.
Figura 27 Espectro de resonancia magnética nuclear de 13C en estado sólido con bandas laterales de rotación identificadas por un asterisco de la Forma VII de atorvastatina.
Figura 28 Espectro de resonancia magnética nuclear de 13C en estado sólido con bandas laterales de rotación identificadas por un asterisco de la Forma VIII de atorvastatina.
Figura 29 Espectro de resonancia magnética nuclear de 13C en estado sólido de la Forma X de atorvastatina.
Figura 30 Espectro Raman de la Forma V.
17
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30204901P | 2001-06-29 | 2001-06-29 | |
| US302049P | 2001-06-29 | ||
| PCT/IB2002/001796 WO2003004470A1 (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2558565T3 true ES2558565T3 (es) | 2016-02-05 |
Family
ID=23166039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02727946.2T Expired - Lifetime ES2558565T3 (es) | 2001-06-29 | 2002-05-21 | Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina) |
Country Status (41)
| Country | Link |
|---|---|
| US (5) | US6605729B1 (es) |
| EP (2) | EP3009423A3 (es) |
| JP (2) | JP3965155B2 (es) |
| KR (1) | KR100609371B1 (es) |
| CN (2) | CN1524073A (es) |
| AP (1) | AP1571A (es) |
| AR (1) | AR036118A1 (es) |
| AU (1) | AU2002258092B2 (es) |
| BG (1) | BG108393A (es) |
| BR (1) | BR0210666A (es) |
| CA (1) | CA2450111C (es) |
| CR (2) | CR7170A (es) |
| CZ (1) | CZ20033478A3 (es) |
| DO (1) | DOP2002000413A (es) |
| EA (1) | EA005317B1 (es) |
| EC (1) | ECSP034928A (es) |
| EE (1) | EE200300597A (es) |
| ES (1) | ES2558565T3 (es) |
| GE (1) | GEP20053546B (es) |
| HR (1) | HRP20031039A2 (es) |
| HU (1) | HUP0400381A2 (es) |
| IL (1) | IL158790A0 (es) |
| MA (1) | MA27044A1 (es) |
| MX (1) | MXPA03010266A (es) |
| MY (1) | MY122907A (es) |
| NO (1) | NO326170B1 (es) |
| NZ (1) | NZ529557A (es) |
| OA (1) | OA12636A (es) |
| PA (1) | PA8549501A1 (es) |
| PE (1) | PE20030124A1 (es) |
| PL (1) | PL367943A1 (es) |
| PY (1) | PY0213405A (es) |
| RS (1) | RS100003A (es) |
| SK (1) | SK16002003A3 (es) |
| SV (1) | SV2003001144A (es) |
| TN (1) | TNSN03147A1 (es) |
| TW (1) | TWI319396B (es) |
| UA (1) | UA74075C2 (es) |
| UY (1) | UY27359A1 (es) |
| WO (1) | WO2003004470A1 (es) |
| ZA (1) | ZA200308731B (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| KR100431038B1 (ko) | 1995-07-17 | 2004-05-12 | 워너-램버트 캄파니 엘엘씨 | 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴) |
| US20080275104A1 (en) * | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US20040072138A1 (en) * | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| CZ20031495A3 (cs) * | 2000-11-03 | 2004-01-14 | Teva Pharmaceutical Industries Ltd. | Forma VII hemi-kalcium atorvastatinu |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2002224952B2 (en) * | 2000-12-27 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| SK16002003A3 (sk) * | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín) |
| US7074818B2 (en) * | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| MXPA04007939A (es) * | 2002-02-15 | 2004-11-26 | Teva Pharma | Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix. |
| MXPA04007995A (es) * | 2002-02-19 | 2004-11-26 | Teva Pharma | Desolvatacion de solvatos de hemicalcio de atorvastatina. |
| US20060122403A1 (en) * | 2002-09-03 | 2006-06-08 | Sanjay Suri | Atorvastatin calcium form vi or hydrates thereof |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
| US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20070270350A1 (en) * | 2003-12-23 | 2007-11-22 | Musc Foundation For Research Development | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions |
| EP1761489A1 (en) * | 2004-03-17 | 2007-03-14 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
| AU2004317570B2 (en) | 2004-03-17 | 2011-01-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| US7875731B2 (en) | 2004-05-05 | 2011-01-25 | Pfizer Inc. | Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid |
| JP2008506764A (ja) * | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| US7674923B2 (en) * | 2004-09-28 | 2010-03-09 | Teva Pharmaceutical Industries Ltd | Process for preparing forms of atorvastatin calcium substantially free of impurities |
| CA2585836A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| WO2006054308A2 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| CA2589537A1 (en) * | 2004-12-02 | 2006-06-08 | Stephen Craig Dyar | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
| EP1688850A1 (en) | 2005-02-07 | 2006-08-09 | Sony Ericsson Mobile Communications AB | Generic parser for electronic devices |
| US8506646B2 (en) * | 2005-04-29 | 2013-08-13 | Warsaw Orthopedic, Inc. | Multi-purpose medical implant devices |
| US8092464B2 (en) * | 2005-04-30 | 2012-01-10 | Warsaw Orthopedic, Inc. | Syringe devices and methods useful for delivering osteogenic material |
| CA2628666A1 (en) * | 2005-11-21 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Atorvastatin formulation |
| EP1923057A1 (en) * | 2005-11-21 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Atorvastatin pharmaceutical formulation |
| WO2007057755A1 (en) | 2005-11-21 | 2007-05-24 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium |
| CA2633268A1 (en) * | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US7834195B2 (en) * | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
| KR100878140B1 (ko) * | 2007-01-29 | 2009-01-12 | 한미약품 주식회사 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
| EP2132171A4 (en) * | 2007-03-02 | 2010-11-17 | Dong A Pharm Co Ltd | NEW CRYSTALLINE FORMS OF PYRROLYLHEPTANIC ACID DERIVATIVES |
| WO2008112887A1 (en) * | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| WO2008123953A1 (en) * | 2007-04-02 | 2008-10-16 | Merck & Co., Inc. | Anti-hypercholesterolemic compound |
| DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
| CN102976996B (zh) * | 2009-05-27 | 2015-08-19 | 峡江和美药业有限公司 | 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用 |
| US9334266B2 (en) | 2009-09-04 | 2016-05-10 | The University Of Toledo | Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| US20140335179A1 (en) * | 2011-07-01 | 2014-11-13 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Micronized crystals of atorvastatin hemicalcium |
| CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
| CN104983702A (zh) * | 2015-07-23 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
| US10450957B2 (en) | 2017-01-23 | 2019-10-22 | United Technologies Corporation | Gas turbine engine with heat pipe system |
| CA3059073A1 (en) | 2017-04-18 | 2018-10-25 | Gemphire Therapeutics Inc. | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
| WO2020013330A1 (ja) * | 2018-07-13 | 2020-01-16 | 協和発酵バイオ株式会社 | ユーコミン酸の非溶媒和物結晶及びその製造方法 |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| JP3254219B2 (ja) | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のｃｉ−９８１製剤およびその製法 |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| KR100431038B1 (ko) | 1995-07-17 | 2004-05-12 | 워너-램버트 캄파니 엘엘씨 | 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴) |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| WO1998004543A1 (en) | 1996-07-29 | 1998-02-05 | Warner-Lambert Company | Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid |
| IN191236B (es) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US7411075B1 (en) * | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| CZ20021642A3 (cs) * | 1999-11-17 | 2003-05-14 | Teva Pharmaceutical Industries Ltd. | Polymorfní formy atorvastatinu vápenatého |
| SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| EP1237865B1 (en) * | 1999-12-17 | 2005-11-16 | Pfizer Science and Technology Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
| WO2001044181A1 (en) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
| CZ20031495A3 (cs) * | 2000-11-03 | 2004-01-14 | Teva Pharmaceutical Industries Ltd. | Forma VII hemi-kalcium atorvastatinu |
| HUP0303555A3 (en) | 2000-11-16 | 2005-08-29 | Teva Pharma | Hydrolysis of [r(r |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2002224952B2 (en) * | 2000-12-27 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| IN190564B (es) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| GB0111077D0 (en) | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| SK16002003A3 (sk) * | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín) |
| US7074818B2 (en) * | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| CA2633268A1 (en) * | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
-
2002
- 2002-05-21 SK SK1600-2003A patent/SK16002003A3/sk unknown
- 2002-05-21 AP APAP/P/2003/002936A patent/AP1571A/en active
- 2002-05-21 ES ES02727946.2T patent/ES2558565T3/es not_active Expired - Lifetime
- 2002-05-21 EA EA200301243A patent/EA005317B1/ru not_active IP Right Cessation
- 2002-05-21 HU HU0400381A patent/HUP0400381A2/hu unknown
- 2002-05-21 CN CNA028130227A patent/CN1524073A/zh active Pending
- 2002-05-21 HR HR20031039A patent/HRP20031039A2/xx not_active Application Discontinuation
- 2002-05-21 CA CA002450111A patent/CA2450111C/en not_active Expired - Fee Related
- 2002-05-21 RS YUP-1000/03A patent/RS100003A/sr unknown
- 2002-05-21 JP JP2003510638A patent/JP3965155B2/ja not_active Expired - Fee Related
- 2002-05-21 OA OA1200300342A patent/OA12636A/en unknown
- 2002-05-21 NZ NZ529557A patent/NZ529557A/en unknown
- 2002-05-21 CZ CZ20033478A patent/CZ20033478A3/cs unknown
- 2002-05-21 EP EP15192682.1A patent/EP3009423A3/en not_active Withdrawn
- 2002-05-21 BR BR0210666-3A patent/BR0210666A/pt not_active IP Right Cessation
- 2002-05-21 PL PL02367943A patent/PL367943A1/xx not_active Application Discontinuation
- 2002-05-21 UA UA20031212658A patent/UA74075C2/uk unknown
- 2002-05-21 EP EP02727946.2A patent/EP1423364B1/en not_active Expired - Lifetime
- 2002-05-21 IL IL15879002A patent/IL158790A0/xx unknown
- 2002-05-21 KR KR1020037016944A patent/KR100609371B1/ko not_active Expired - Fee Related
- 2002-05-21 EE EEP200300597A patent/EE200300597A/xx unknown
- 2002-05-21 MX MXPA03010266A patent/MXPA03010266A/es active IP Right Grant
- 2002-05-21 WO PCT/IB2002/001796 patent/WO2003004470A1/en not_active Ceased
- 2002-05-21 AU AU2002258092A patent/AU2002258092B2/en not_active Ceased
- 2002-05-21 GE GE5360A patent/GEP20053546B/en unknown
- 2002-05-21 CN CNA2007101598559A patent/CN101215253A/zh active Pending
- 2002-06-05 DO DO2002000413A patent/DOP2002000413A/es unknown
- 2002-06-06 PY PY200200213405A patent/PY0213405A/es unknown
- 2002-06-26 PE PE2002000569A patent/PE20030124A1/es not_active Application Discontinuation
- 2002-06-27 UY UY27359A patent/UY27359A1/es not_active Application Discontinuation
- 2002-06-28 TW TW091114336A patent/TWI319396B/zh not_active IP Right Cessation
- 2002-06-28 AR ARP020102428A patent/AR036118A1/es unknown
- 2002-06-28 US US10/184,669 patent/US6605729B1/en not_active Expired - Lifetime
- 2002-06-28 PA PA20028549501A patent/PA8549501A1/es unknown
- 2002-06-28 MY MYPI20022466A patent/MY122907A/en unknown
- 2002-06-28 SV SV2002001144A patent/SV2003001144A/es not_active Application Discontinuation
-
2003
- 2003-06-06 US US10/456,046 patent/US7144915B2/en not_active Expired - Lifetime
- 2003-07-08 TN TNPCT/IB2002/001796A patent/TNSN03147A1/fr unknown
- 2003-11-10 ZA ZA200308731A patent/ZA200308731B/en unknown
- 2003-11-26 CR CR7170A patent/CR7170A/es not_active Application Discontinuation
- 2003-11-28 BG BG108393A patent/BG108393A/bg unknown
- 2003-12-18 NO NO20035675A patent/NO326170B1/no unknown
- 2003-12-22 MA MA27456A patent/MA27044A1/fr unknown
- 2003-12-29 EC EC2003004928A patent/ECSP034928A/es unknown
-
2006
- 2006-05-25 US US11/441,268 patent/US20060241169A1/en not_active Abandoned
-
2007
- 2007-04-11 JP JP2007103465A patent/JP2007182460A/ja active Pending
- 2007-10-25 US US11/977,459 patent/US20080214651A1/en not_active Abandoned
-
2008
- 2008-02-15 CR CR9741A patent/CR9741A/es not_active Application Discontinuation
- 2008-07-14 US US12/172,503 patent/US20080287521A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4700442A1 (es) | Forma iii cristalina de sal de calcio de acido [r-(r*,r*)] -2-(4-fluorofenil)-b,s-dihidroxi-5-(1-metiletil)-3-fenil-4- [(fenilamino)carbonil] -1h-pirrol-1-heptanoico (2:1) | |
| AR036118A1 (es) | Formas cristalinas v, vi, vii, viii, ix, x, xi, xii, xiii, xiv, xv, xvi, xvii, xviii, xix, de la sal de calcio del acido [r-(r*, r*)]-2-(4-fluorofenil)-beta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico (2:1) | |
| NZ527048A (en) | Crystalline forms of atorvastatin | |
| DE60012859D1 (de) | Bestimmung der Orientierung von Bildern die einen blauen Himmel enthalten | |
| IL155734A0 (en) | Atorvastatin hemi-calcium form vii | |
| ATE393123T1 (de) | Herstellung von eisenverbindungen durch hydrothermale umwandlung | |
| DE50008636D1 (de) | Zylinderkopfdichtung | |
| AU2003297594A1 (en) | Crystalline form f of atorvastatin hemi-calcium salt | |
| DE50004486D1 (de) | Mehrschichtige Zylinderkopfdichtung | |
| TH61086A (th) | รูปแบบผลึกของเกลือแคลเซียม (2:1) ของ [r-(r*,r*)] -2-(4-ฟลูออโรเฟนิล) -(สูตร),(สูตร)-ไดไฮดรอกซิ-5-(1-เมธิลเอธิล)-3-เฟนิล-4[(เฟนิลอะมิโน)คาร์บอนิล] -1h-พิร์โรล-1-เฮปทานออบิคแอซิด | |
| DE50008083D1 (de) | Mehrlagige metallische Zylinderkopfdichtung | |
| TH32710A (th) | ผลึกรูปแบบ lll ของเกลือแคลเซียม (2:1) ของกรด [R-(R*,R*)]- 2-(4-ฟลูออโรเฟนิล)-เบตา,เดลตา-ไดไฮดรอกซิ-5-(1-เมธิลเอธิล)'-3-เฟนิล- 4-[(เฟนิลอะมิโน)คาร์บอนิล]-1H-พิร์โรล-1-เฮปทานออิค | |
| TH13382B (th) | ผลึกรูปแบบ lll ของเกลือแคลเซียม (2:1) ของกรด [R-(R*,R*)]- 2-(4-ฟลูออโรเฟนิล)-เบตา,เดลตา-ไดไฮดรอกซิ-5-(1-เมธิลเอธิล)'-3-เฟนิล- 4-[(เฟนิลอะมิโน)คาร์บอนิล]-1H-พิร์โรล-1-เฮปทานออิค | |
| DE50006505D1 (de) | Kolbenmotor mit einem zylinder aus leichtmetall | |
| IL128343A0 (en) | Process for the preparation of 2-aryl-5-(perfluoroalkyl) pyrrole compounds from N-(arylmethylene)-1-chloro-1-(perfluoroalkyl) methylamine compounds | |
| CA2521776A1 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) | |
| ATA19192002A (de) | Doppelzylinderschloss | |
| FR2829196B1 (fr) | Labyrinthe d'accrochage pour piton escamotable a double verrouillage | |
| RU99108621A (ru) | Суспензия для изготовления пресс-порошков магний-цинковых ферритов распылительной сушкой | |
| RU99111535A (ru) | Радиопоглощающий материал | |
| RU2001104292A (ru) | Пневмоцилиндр | |
| RU2001106870A (ru) | Способ получения пигмента черного цвета | |
| RU2002124897A (ru) | Управляемый резонатор № 1 | |
| TH13381B (th) | ผลึกเกลือแคลเซียม (2:1) ของ [r-(r*,r*)]?-2-(4-ฟลูออโรเฟนิล-(สูตร)-ไดไฮดรอกซิ-5-(1-เมธิลเอธิล)?-3-เฟนิล-4-[(เฟนิลอะมิโน)คาร์บอนิล]-1h-พิร์โรล-1-เฮปทานออิค ?แอซิด | |
| TH34638A (th) | ผลึกเกลือแคลเซียม (2:1) ของ [r-(r*,r*)]?-2-(4-ฟลูออโรเฟนิล-(สูตร)-ไดไฮดรอกซิ-5-(1-เมธิลเอธิล)?-3-เฟนิล-4-[(เฟนิลอะมิโน)คาร์บอนิล]-1h-พิร์โรล-1-เฮปทานออิค ?แอซิด |